LYRA

Lyra Therapeutics Inc
CAPPED RATING

Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. It's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. The company's product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.

Lyra Therapeutics Inc (LYRA) is rated D+ (1.7/5) on Deltasharpe Prism, scored against Healthcare sector peers. Its strongest pillar is Value (C+); its weakest is Profitability (F).

Quantitative Factor Evaluation • Updated

Overall Rating
1.7 / 5.0
D+
Value
C+
Factor Score 2.7 / 5.0
Growth
D
Factor Score 1.3 / 5.0
Profitability
F
Factor Score 0.0 / 5.0
Momentum
C
Factor Score 2.4 / 5.0
Revisions
C-
Factor Score 1.9 / 5.0

Prism grades are automated quantitative screens, not buy, sell or hold recommendations, and not investment advice. Data may be delayed or contain errors. Terms

Ratings of B- and above are for members.

Register free to see every rating — your first 2 weeks of Premium are on us.

Register — 2 weeks free

Underlying Financial Metrics

P/E Ratio 0.0
EV / EBITDA 0.7
Rev Growth YoY -96.7%
Gross Margin N/M
Price Return 3M -34.9%
Price Return 12M -93.0%
Catalyst Signal 0.00
Market Cap N/A
TTM Revenue N/A
Price / Sales 2.1
ROE N/M

Historical Factor Score Progression

Date Value Growth Profitability Momentum Revisions Overall
2026-08-05 C+ (2.7) D (1.3) F (0.0) C (2.4) C- (1.9) D+ (1.7)
2026-08-04 C+ (2.7) D (1.3) F (0.0) C (2.4) C- (1.9) D+ (1.7)
2026-08-03 C+ (2.7) C- (2.0) D (1.3) C (2.4) C- (2.0) C- (2.1)
2026-08-02 C+ (2.7) C- (2.0) D (1.3) C (2.4) C- (1.9) C- (2.1)
2026-07-29 C+ (2.6) F (0.2) D- (1.0) F (0.5) D+ (1.5) D- (1.1)
Page 1 of 5